Stock Analysis on Net

IQVIA Holdings Inc. (NYSE:IQV)

This company has been moved to the archive! The financial data has not been updated since November 1, 2023.

Common Stock Valuation Ratios (Price Multiples) 
Quarterly Data

Microsoft Excel

Historical Valuation Ratios (Summary)

IQVIA Holdings Inc., historical price multiples (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Price to earnings (P/E) 29.44 36.61 33.11 38.65 31.49 35.65 38.49 45.78 63.98 77.46 108.86 132.09 184.54 233.99 126.65 166.58 116.69 127.38 108.28 107.95
Price to operating profit (P/OP) 17.71 21.74 19.68 23.44 19.77 24.14 26.86 31.75 40.26 42.59 50.59 50.41 53.42 49.42 35.83 40.95 34.81 39.58 34.96 37.73
Price to sales (P/S) 2.21 2.73 2.41 2.93 2.60 2.93 2.96 3.19 3.63 3.64 3.71 3.24 2.96 2.82 2.44 2.87 2.62 2.94 2.55 2.69
Price to book value (P/BV) 5.66 6.98 5.89 7.31 6.96 7.73 7.02 7.32 8.42 8.16 7.48 6.14 5.56 5.52 4.91 5.30 4.64 4.82 4.06 4.16 3.36 3.31 2.51

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. IQVIA Holdings Inc. P/E ratio increased from Q1 2023 to Q2 2023 but then decreased significantly from Q2 2023 to Q3 2023.
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. IQVIA Holdings Inc. P/OP ratio increased from Q1 2023 to Q2 2023 but then decreased significantly from Q2 2023 to Q3 2023.
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. IQVIA Holdings Inc. P/S ratio increased from Q1 2023 to Q2 2023 but then decreased significantly from Q2 2023 to Q3 2023.
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. IQVIA Holdings Inc. P/BV ratio increased from Q1 2023 to Q2 2023 but then decreased significantly from Q2 2023 to Q3 2023.

Price to Earnings (P/E)

IQVIA Holdings Inc., historical P/E calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
No. shares of common stock outstanding1 182,500,000 183,122,255 185,549,128 185,722,621 185,740,023 186,507,930 189,279,035 190,485,264 191,039,501 191,612,337 191,661,174 191,281,286 191,725,778 191,270,966 190,963,771 192,339,093 194,037,571 195,894,501 197,240,698 197,599,861 202,306,281 202,586,895 207,684,876
Selected Financial Data (US$)
Net income (loss) attributable to IQVIA Holdings Inc. (in millions) 303 297 289 227 283 256 325 318 261 175 212 119 101 (23) 82 16 57 60 58 69 60 61 69
Earnings per share (EPS)2 6.12 5.99 5.69 5.87 6.36 6.22 5.70 5.07 4.01 3.17 2.13 1.46 0.92 0.69 1.13 0.99 1.26 1.26 1.26 1.31 0.00 0.00 0.00
Share price1, 3 180.01 219.13 188.23 227.03 200.42 221.74 219.40 232.18 256.89 245.37 232.30 192.66 169.40 161.48 142.59 165.42 146.74 160.61 136.14 141.49 119.92 120.45 99.02
Valuation Ratio
P/E ratio4 29.44 36.61 33.11 38.65 31.49 35.65 38.49 45.78 63.98 77.46 108.86 132.09 184.54 233.99 126.65 166.58 116.69 127.38 108.28 107.95
Benchmarks
P/E Ratio, Competitors5
AbbVie Inc. 38.27 30.55 34.43 22.62 19.16 19.44 21.64 22.07 27.34 30.62 39.63 40.17 22.60 23.92 14.70 17.82
Amgen Inc. 18.09 16.31 16.18 19.56 21.00 20.03 22.23 21.05 21.91 22.56 19.20 18.82 17.25 19.97 17.70 17.07
Bristol-Myers Squibb Co. 13.01 15.93 19.43 23.97 23.71 24.14 25.64 20.92 144.77 41.99
Danaher Corp. 24.76 29.99 25.00 25.65 26.65 32.73 32.15 29.94 38.81 37.87 39.26 44.49 46.61 41.91 35.88 38.34
Eli Lilly & Co. 110.43 76.21 65.16 50.08 55.53 51.05 45.29 40.66 40.07 40.34 28.77 31.95 22.54 25.59 26.56 16.19
Gilead Sciences Inc. 17.10 17.88 17.75 22.68 29.30 18.66 17.25 12.36 11.44 16.83 277.25 641.48 59.19 19.58 16.45
Johnson & Johnson 10.12 33.35 33.43 22.97 23.52 24.98 23.95 20.93 23.98 25.51 28.35 28.92 22.51 25.68 23.06 25.99
Merck & Co. Inc. 56.85 86.53 22.92 19.21 16.41 13.36 15.70 14.78 28.65 34.23 28.00 26.72 17.67 19.70 19.18 20.60
Moderna Inc. 34.67 10.70 6.43 4.82 5.19 4.21 5.00 16.31 48.08 107.74
Pfizer Inc. 16.60 9.42 7.44 7.58 8.81 9.56 11.11 11.76 14.03 20.05 20.15 19.62 25.36 14.99 13.04 11.63
Regeneron Pharmaceuticals Inc. 22.35 19.48 19.77 19.68 14.98 11.67 9.15 8.37 9.96 10.38 13.27 15.09 19.91 22.27 28.35 19.86
Thermo Fisher Scientific Inc. 29.57 37.01 34.99 30.55 27.64 31.09 28.15 27.35 29.43 24.63 23.23 27.89 38.43 44.19 35.50 33.36

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Data adjusted for splits and stock dividends.

2 Q3 2023 Calculation
EPS = (Net income (loss) attributable to IQVIA Holdings Inc.Q3 2023 + Net income (loss) attributable to IQVIA Holdings Inc.Q2 2023 + Net income (loss) attributable to IQVIA Holdings Inc.Q1 2023 + Net income (loss) attributable to IQVIA Holdings Inc.Q4 2022) ÷ No. shares of common stock outstanding
= (303,000,000 + 297,000,000 + 289,000,000 + 227,000,000) ÷ 182,500,000 = 6.12

3 Closing price as at the filing date of IQVIA Holdings Inc. Quarterly or Annual Report.

4 Q3 2023 Calculation
P/E ratio = Share price ÷ EPS
= 180.01 ÷ 6.12 = 29.44

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. IQVIA Holdings Inc. P/E ratio increased from Q1 2023 to Q2 2023 but then decreased significantly from Q2 2023 to Q3 2023.

Price to Operating Profit (P/OP)

IQVIA Holdings Inc., historical P/OP calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
No. shares of common stock outstanding1 182,500,000 183,122,255 185,549,128 185,722,621 185,740,023 186,507,930 189,279,035 190,485,264 191,039,501 191,612,337 191,661,174 191,281,286 191,725,778 191,270,966 190,963,771 192,339,093 194,037,571 195,894,501 197,240,698 197,599,861 202,306,281 202,586,895 207,684,876
Selected Financial Data (US$)
Income from operations (in millions) 481 524 471 379 472 453 495 463 302 286 342 289 187 62 193 166 204 197 210 207 181 170 183
Operating profit per share2 10.16 10.08 9.57 9.69 10.14 9.18 8.17 7.31 6.38 5.76 4.59 3.82 3.17 3.27 3.98 4.04 4.22 4.06 3.89 3.75 0.00 0.00 0.00
Share price1, 3 180.01 219.13 188.23 227.03 200.42 221.74 219.40 232.18 256.89 245.37 232.30 192.66 169.40 161.48 142.59 165.42 146.74 160.61 136.14 141.49 119.92 120.45 99.02
Valuation Ratio
P/OP ratio4 17.71 21.74 19.68 23.44 19.77 24.14 26.86 31.75 40.26 42.59 50.59 50.41 53.42 49.42 35.83 40.95 34.81 39.58 34.96 37.73
Benchmarks
P/OP Ratio, Competitors5
AbbVie Inc. 16.55 15.26 16.15 14.78 14.52 14.12 14.57 14.21 12.41 13.12 17.23 16.32 14.42 15.23 9.13 10.82
Amgen Inc. 15.45 13.71 14.25 13.40 14.89 14.08 15.88 16.24 16.73 17.48 15.26 14.96 13.82 15.84 14.22 13.84
Bristol-Myers Squibb Co. 14.14 16.24 17.09 18.29 17.79 18.62 20.32 19.84 39.45 33.97 27.33 24.42
Danaher Corp. 23.61 27.01 21.31 20.97 20.71 25.91 26.48 25.14 32.12 30.83 32.62 36.91 46.28 43.09 35.22 34.47
Eli Lilly & Co. 93.27 69.42 59.60 43.88 46.48 39.20 36.49 35.70 37.21 42.01 31.17 32.66 22.98 25.58 24.82 27.08
Gilead Sciences Inc. 12.16 11.57 11.21 14.21 16.27 11.02 10.78 7.76 7.27 8.88 18.31 19.38 29.86 21.83 20.66
Johnson & Johnson 15.69 18.91 18.26 17.62 19.64 20.45 21.06 18.68 18.99 20.14 21.12 21.84 19.46 19.66 18.67 19.83
Merck & Co. Inc. 33.75 44.67 18.53 15.55 13.85 11.72 14.29 15.39 30.71 38.03 30.14 23.89 16.00 17.23 15.88 17.47
Moderna Inc. 81.57 10.61 5.71 4.28 4.66 3.79 4.59 15.13 44.01 101.69
Pfizer Inc. 17.49 9.17 6.74 6.80 7.82 9.11 11.49 13.30 16.37 19.83 22.85 23.12 22.27 22.17 17.42 14.36
Regeneron Pharmaceuticals Inc. 21.13 19.32 18.68 18.01 12.91 9.68 7.98 7.55 9.32 9.65 13.32 14.82 20.36 23.98 26.60 19.01
Thermo Fisher Scientific Inc. 25.59 31.55 29.54 25.30 21.43 23.99 21.84 21.07 23.87 19.77 18.53 22.81 31.49 36.59 28.44 26.84

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Data adjusted for splits and stock dividends.

2 Q3 2023 Calculation
Operating profit per share = (Income from operationsQ3 2023 + Income from operationsQ2 2023 + Income from operationsQ1 2023 + Income from operationsQ4 2022) ÷ No. shares of common stock outstanding
= (481,000,000 + 524,000,000 + 471,000,000 + 379,000,000) ÷ 182,500,000 = 10.16

3 Closing price as at the filing date of IQVIA Holdings Inc. Quarterly or Annual Report.

4 Q3 2023 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 180.01 ÷ 10.16 = 17.71

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. IQVIA Holdings Inc. P/OP ratio increased from Q1 2023 to Q2 2023 but then decreased significantly from Q2 2023 to Q3 2023.

Price to Sales (P/S)

IQVIA Holdings Inc., historical P/S calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
No. shares of common stock outstanding1 182,500,000 183,122,255 185,549,128 185,722,621 185,740,023 186,507,930 189,279,035 190,485,264 191,039,501 191,612,337 191,661,174 191,281,286 191,725,778 191,270,966 190,963,771 192,339,093 194,037,571 195,894,501 197,240,698 197,599,861 202,306,281 202,586,895 207,684,876
Selected Financial Data (US$)
Revenues (in millions) 3,736 3,728 3,652 3,739 3,562 3,541 3,568 3,636 3,391 3,438 3,409 3,298 2,786 2,521 2,754 2,895 2,769 2,740 2,684 2,688 2,594 2,567 2,563
Sales per share2 81.40 80.17 78.11 77.59 77.03 75.79 74.14 72.84 70.85 67.49 62.68 59.38 57.14 57.19 58.43 57.65 56.08 54.65 53.40 52.69 0.00 0.00 0.00
Share price1, 3 180.01 219.13 188.23 227.03 200.42 221.74 219.40 232.18 256.89 245.37 232.30 192.66 169.40 161.48 142.59 165.42 146.74 160.61 136.14 141.49 119.92 120.45 99.02
Valuation Ratio
P/S ratio4 2.21 2.73 2.41 2.93 2.60 2.93 2.96 3.19 3.63 3.64 3.71 3.24 2.96 2.82 2.44 2.87 2.62 2.94 2.55 2.69
Benchmarks
P/S Ratio, Competitors5
AbbVie Inc. 4.52 4.74 4.60 4.61 4.44 4.28 4.76 4.53 3.73 3.80 4.07 4.05 4.10 4.59 3.64 4.22
Amgen Inc. 5.34 5.14 5.14 5.17 5.85 5.35 5.21 5.10 5.04 5.37 5.68 5.64 5.33 6.30 5.96 6.03
Bristol-Myers Squibb Co. 2.40 2.81 3.10 3.29 3.39 3.39 3.41 3.16 2.85 3.44 3.28 3.16 3.66 3.97 4.45 5.52
Danaher Corp. 5.63 6.77 5.76 5.79 5.66 6.59 6.68 6.37 7.91 7.72 7.27 7.01 8.15 7.48 6.34 6.29
Eli Lilly & Co. 17.18 16.78 13.38 10.96 11.46 9.99 9.47 8.01 8.62 9.16 6.88 8.06 5.41 6.26 6.36 6.03
Gilead Sciences Inc. 3.69 3.61 3.70 3.86 3.64 2.84 2.86 2.85 3.11 3.30 3.31 3.24 3.29 3.95 4.34 4.00
Johnson & Johnson 4.01 4.84 4.60 4.34 4.69 4.80 5.00 4.66 4.69 5.08 5.09 5.15 4.73 4.84 4.78 4.79
Merck & Co. Inc. 4.42 4.62 5.16 4.71 4.25 3.87 4.12 3.96 4.32 4.05 4.23 3.93 4.30 4.38 4.05 4.33
Moderna Inc. 3.38 4.14 3.57 2.92 2.76 3.29 2.82 3.45 10.53 27.41 33.34 309.64
Pfizer Inc. 2.51 2.58 2.32 2.37 2.63 2.77 3.00 3.18 4.04 4.78 4.84 4.50 4.71 4.69 4.21 3.66
Regeneron Pharmaceuticals Inc. 6.81 6.61 6.69 7.01 5.87 4.66 4.40 4.20 5.14 5.20 5.78 6.24 7.62 8.31 8.10 5.34
Thermo Fisher Scientific Inc. 4.05 4.87 4.81 4.73 4.40 5.40 5.20 5.39 6.45 5.54 5.13 5.52 6.58 6.24 5.08 4.83

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Data adjusted for splits and stock dividends.

2 Q3 2023 Calculation
Sales per share = (RevenuesQ3 2023 + RevenuesQ2 2023 + RevenuesQ1 2023 + RevenuesQ4 2022) ÷ No. shares of common stock outstanding
= (3,736,000,000 + 3,728,000,000 + 3,652,000,000 + 3,739,000,000) ÷ 182,500,000 = 81.40

3 Closing price as at the filing date of IQVIA Holdings Inc. Quarterly or Annual Report.

4 Q3 2023 Calculation
P/S ratio = Share price ÷ Sales per share
= 180.01 ÷ 81.40 = 2.21

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. IQVIA Holdings Inc. P/S ratio increased from Q1 2023 to Q2 2023 but then decreased significantly from Q2 2023 to Q3 2023.

Price to Book Value (P/BV)

IQVIA Holdings Inc., historical P/BV calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
No. shares of common stock outstanding1 182,500,000 183,122,255 185,549,128 185,722,621 185,740,023 186,507,930 189,279,035 190,485,264 191,039,501 191,612,337 191,661,174 191,281,286 191,725,778 191,270,966 190,963,771 192,339,093 194,037,571 195,894,501 197,240,698 197,599,861 202,306,281 202,586,895 207,684,876
Selected Financial Data (US$)
Equity attributable to IQVIA Holdings Inc.’s stockholders (in millions) 5,805 5,748 5,932 5,765 5,347 5,352 5,919 6,042 5,829 5,760 5,953 6,001 5,846 5,591 5,542 6,003 6,131 6,523 6,615 6,714 7,215 7,364 8,196
Book value per share (BVPS)2 31.81 31.39 31.97 31.04 28.79 28.70 31.27 31.72 30.51 30.06 31.06 31.37 30.49 29.23 29.02 31.21 31.60 33.30 33.54 33.98 35.66 36.35 39.46
Share price1, 3 180.01 219.13 188.23 227.03 200.42 221.74 219.40 232.18 256.89 245.37 232.30 192.66 169.40 161.48 142.59 165.42 146.74 160.61 136.14 141.49 119.92 120.45 99.02
Valuation Ratio
P/BV ratio4 5.66 6.98 5.89 7.31 6.96 7.73 7.02 7.32 8.42 8.16 7.48 6.14 5.56 5.52 4.91 5.30 4.64 4.82 4.06 4.16 3.36 3.31 2.51
Benchmarks
P/BV Ratio, Competitors5
AbbVie Inc. 20.61 20.62 19.68 15.52 16.06 16.76 16.59 16.53 15.20 16.23 14.91 14.18 10.93 11.31
Amgen Inc. 17.87 19.19 23.95 35.01 39.30 54.46 138.87 18.51 14.95 15.72 14.57 14.53 11.57 13.67 14.33 13.84 11.47 10.37 9.92
Bristol-Myers Squibb Co. 3.72 3.97 4.46 4.88 4.85 4.90 5.07 4.07 3.48 4.15 3.73 3.55 2.87 2.82 2.77 2.80 5.30 4.63 4.91
Danaher Corp. 2.78 3.65 3.33 3.64 3.77 4.36 4.36 4.16 5.11 4.82 4.46 3.93 4.38 3.90 3.68 3.72 3.02 3.19 2.88
Eli Lilly & Co. 49.10 44.75 33.11 29.36 33.27 34.00 29.75 25.28 30.85 38.00 25.41 35.07 26.02 35.12 47.73 51.67 31.28 39.03 46.37
Gilead Sciences Inc. 4.50 4.63 4.72 4.90 4.63 3.82 3.91 3.65 3.94 4.41 4.40 4.33 4.30 4.79 4.40 3.93 4.02 3.58 3.83
Johnson & Johnson 4.92 5.79 6.00 5.37 6.04 6.01 6.36 5.90 6.10 6.51 6.51 6.72 5.93 6.19 6.46 6.61 5.84 5.78 6.39
Merck & Co. Inc. 6.35 6.96 6.38 6.07 5.63 5.12 5.44 5.05 5.76 5.73 7.30 7.46 6.97 7.47 7.43 7.83 7.87 7.82 7.31
Moderna Inc. 2.20 2.47 2.71 2.81 3.15 4.06 3.61 4.31 11.37 25.06 16.79 24.16 9.67 9.88 12.03 8.21 4.29 3.25 5.29
Pfizer Inc. 1.80 2.04 2.14 2.48 2.83 3.21 3.37 3.35 3.69 3.78 3.27 2.98 3.10 3.31 3.16 3.00 3.14 3.42 3.84
Regeneron Pharmaceuticals Inc. 3.58 3.49 3.52 3.77 3.75 3.21 3.65 3.60 4.04 4.26 4.44 4.81 6.21 7.34 5.33 3.79 3.48 3.38 3.74
Thermo Fisher Scientific Inc. 3.88 4.84 4.99 4.83 4.46 5.47 5.23 5.18 6.51 5.75 5.25 5.15 5.89 5.48 4.56 4.16 4.15 3.83 4.02

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Data adjusted for splits and stock dividends.

2 Q3 2023 Calculation
BVPS = Equity attributable to IQVIA Holdings Inc.’s stockholders ÷ No. shares of common stock outstanding
= 5,805,000,000 ÷ 182,500,000 = 31.81

3 Closing price as at the filing date of IQVIA Holdings Inc. Quarterly or Annual Report.

4 Q3 2023 Calculation
P/BV ratio = Share price ÷ BVPS
= 180.01 ÷ 31.81 = 5.66

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. IQVIA Holdings Inc. P/BV ratio increased from Q1 2023 to Q2 2023 but then decreased significantly from Q2 2023 to Q3 2023.